8-KMaterial AgreementsRegulation FDExhibits & Filings

STRYKER CORP 8-K Report, Material Agreement (Feb 16, 2016)

Filed February 16, 2016For Securities:SYK

Summary

Stryker Corporation (SYK) announced on February 16, 2016, that it has entered into a definitive agreement to acquire Charger Holding Corp., the parent company of Physio-Control International, Inc., for $1.28 billion on a debt-free, cash-free basis, subject to closing adjustments. This strategic acquisition is expected to significantly enhance Stryker's emergency medical services product portfolio by integrating Physio-Control's leading offerings in monitors/defibrillators, AEDs, and CPR-assist devices. The transaction is subject to customary closing conditions, including regulatory approvals such as the expiration of the Hart-Scott-Rodino waiting period and foreign competition laws, as well as other standard conditions. The merger agreement outlines typical representations, warranties, and covenants, along with indemnification provisions for Stryker. The deal is anticipated to close by August 12, 2016, unless extended under certain circumstances.

Key Highlights

  • 1Stryker to acquire Charger Holding Corp. (parent of Physio-Control) for $1.28 billion.
  • 2Acquisition enhances Stryker's offerings in emergency medical services and patient handling.
  • 3Physio-Control is a leader in monitors/defibrillators, AEDs, and CPR-assist devices.
  • 4Transaction is on a debt-free, cash-free basis, subject to working capital adjustments.
  • 5Closing is contingent upon regulatory approvals, including HSR Act and foreign competition laws.
  • 6Customary merger agreement terms, including representations, warranties, and indemnification.
  • 7Expected closing date by August 12, 2016, with potential extensions.

Frequently Asked Questions

The acquisition of Charger Holding Corp., the parent of Physio-Control International, Inc., is designed to significantly bolster Stryker's presence and offerings in the emergency medical services market. Physio-Control is a leader in critical care technologies such as monitors/defibrillators, automated external defibrillators (AEDs), and CPR-assist devices, which are expected to complement and expand Stryker's existing product portfolio in this segment.

The total consideration for the acquisition is $1.28 billion. This amount is on a debt-free, cash-free basis and is subject to customary closing adjustments related to working capital and other specified items outlined in the merger agreement.

The consummation of the merger is subject to several conditions, including the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in the United States. Additionally, Stryker must obtain required consents and approvals under various foreign competition laws. Other customary closing conditions include the absence of legal prohibitions, accuracy of representations and warranties (subject to material adverse effect standards), and compliance with covenants by both parties.

The merger agreement stipulates that the transaction is expected to be completed by August 12, 2016. However, this date may be extended under certain specified exceptions outlined in the agreement, providing flexibility for regulatory or other closing requirements.